Acumen Pharmaceuticals, Inc. — Q3 2022 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2022. Unaudited. Amounts below are in U.S. dollars; financial statement figures are in millions unless otherwise noted.
Business context and reporting period
Acumen is a clinical-stage biopharmaceutical company focused on ACU193, an antibody targeting amyloid-beta oligomers for early Alzheimer’s disease. The company reported no product revenue; it expects no product sales revenue unless and until a candidate completes development and receives regulatory approval.
Its Phase 1 INTERCEPT-AD trial is evaluating safety, tolerability, and proof of mechanism in approximately 62 patients. The FDA granted ACU193 Fast Track designation in October 2022. As of November 11, 17 trial sites were active and enrollment was ongoing.
Key financial metrics
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Research and development expense | $8.3 | $1.8 | $21.6 | $6.6 |
| General and administrative expense | $3.1 | $2.1 | $9.4 | $4.5 |
| Total operating expenses / operating loss | $11.4 | $3.9 | $31.0 | $11.2 |
| Net loss | $10.7 | $3.9 | $30.0 | $92.3 |
| Basic and diluted loss per share | $0.26 | $0.10 | $0.74 | $7.00 |
- Liquidity: Cash and cash equivalents were $157.5 million and marketable securities were $42.7 million at September 30, 2022, totaling $200.2 million. Working capital was $195.9 million.
- Cash flow: Net cash used in operating activities was $24.0 million for the first nine months of 2022, versus $14.3 million in 2021. Investing activities provided $59.6 million, largely from maturities and sales of securities. Financing activities used $0.3 million. Cash increased $35.4 million during the period.
- Debt and liabilities: Total liabilities were $6.6 million, primarily current operating liabilities; the filing reports no debt balance. Operating lease liabilities were $0.1 million.
- Margins: Not meaningful because the company had no product revenue.
Material changes versus the prior comparable period
- Quarterly operating expenses rose $7.4 million year over year, primarily from increased clinical-trial and development costs. R&D expense increased $6.5 million, reflecting higher CRO, materials, personnel, consulting, and drug-safety costs.
- For the nine-month period, operating expenses increased $19.8 million, led by R&D, which increased $15.0 million, and G&A, which increased $4.8 million.
- Nine-month net loss was lower than in 2021 despite higher operating expenses. The prior-year loss included $81.2 million of noncash expense from changes in fair value of preferred-stock tranche rights and warrant liabilities; these items were absent in 2022.
- Marketable securities declined from $103.7 million at December 31, 2021 to $42.7 million at September 30, 2022, while cash and cash equivalents increased from $122.2 million to $157.5 million. The filing attributes investing cash inflows mainly to security maturities and sales.
- Unrealized losses on available-for-sale securities were $0.7 million for the first nine months of 2022, principally related to interest-rate and credit-spread movements. The company recorded no other-than-temporary impairment.
Outlook, commentary, risks, and unusual items
- Management expects current cash and marketable securities to fund operating expenses and capital expenditures through 2025, based on its current operating plan and assumptions. The filing cautions that actual cash use could be faster and that additional funding may be needed.
- Management anticipated completing INTERCEPT-AD enrollment in Q1 2023 and reporting topline results in the second half of 2023. These are forward-looking estimates, not guaranteed outcomes.
- Site activation and enrollment had been delayed, which the company attributed principally to COVID-19 effects. It expanded the expected number of sites; further delays remain possible.
- The company expects expenses and operating losses to increase as it advances ACU193, expands capabilities, and operates as a public company. It may need additional financing; equity financing could dilute shareholders, while debt, collaborations, or licensing could impose restrictions or require relinquishing rights.
- Key uncertainties include clinical safety and efficacy, enrollment and trial timing, regulatory approval, reliance on third-party manufacturers and research organizations, competition, and access to capital. The company also cites potential effects from COVID-19, geopolitical events, inflation, rising interest rates, and supply disruptions.
- The July 2022 shelf registration permits up to $200 million of securities offerings, including a $50 million at-the-market program. No ATM shares had been sold by September 30, 2022.
- No material legal proceedings were reported. Management concluded disclosure controls and procedures were effective as of September 30, 2022, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether enrollment and topline reporting for INTERCEPT-AD remain on the stated schedule, and what the trial data show on safety, target engagement, and proof of mechanism.
- Whether the stated cash runway through 2025 remains supported by actual spending, clinical-development plans, and market conditions.
- How quarterly R&D spending, operating cash use, and securities maturities evolve as the trial progresses.
- Whether the company uses its shelf registration or ATM program, and the resulting dilution or financing terms.
- That Fast Track designation facilitates certain FDA interactions and review options but does not ensure faster approval or eventual marketing approval.